Patents by Inventor Jeffrey N. Hemenway

Jeffrey N. Hemenway has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID FORMS OF FXR AGONISTS
    Publication number: 20230190721
    Abstract: Disclosed herein are novel solid forms of FXR agonists. The disclosure also relates to pharmaceutical compositions containing one or more of the solid forms disclosed herein, as well as methods of using the solid forms in the treatment of conditions mediated by FXR. The disclosure also relates to methods for obtaining such solid forms.
    Type: Application
    Filed: October 31, 2022
    Publication date: June 22, 2023
    Inventors: Derek M. Dalton, Peter C. Fung, Nolan Griggs, Jeffrey N. Hemenway, Olga V. Lapina, Matthew M. Logan, Sean T. Neville, Bryan J. Reynolds, Hui-Wen Shih, Anna M. Wagner
  • Solid forms of FXR agonists
    Patent number: 11524005
    Abstract: Disclosed herein are novel solid forms of FXR agonists. The disclosure also relates to pharmaceutical compositions containing one or more of the solid forms disclosed herein, as well as methods of using the solid forms in the treatment of conditions mediated by FXR. The disclosure also relates to methods for obtaining such solid forms.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: December 13, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Derek M. Dalton, Peter C. Fung, Nolan Griggs, Jeffrey N. Hemenway, Olga V. Lapina, Matthew M. Logan, Sean T. Neville, Bryan J. Reynolds, Hui-Wen Shih, Anna M. Wagner
  • SOLID FORMS OF FXR AGONISTS
    Publication number: 20200281911
    Abstract: Disclosed herein are novel solid forms of FXR agonists. The disclosure also relates to pharmaceutical compositions containing one or more of the solid forms disclosed herein, as well as methods of using the solid forms in the treatment of conditions mediated by FXR. The disclosure also relates to methods for obtaining such solid forms.
    Type: Application
    Filed: February 14, 2020
    Publication date: September 10, 2020
    Inventors: Derek M. Dalton, Peter C. Fung, Nolan Griggs, Jeffrey N. Hemenway, Olga V. Lapina, Matthew M. Logan, Sean T. Neville, Bryan J. Reynolds, Hui-Wen Shih, Anna M. Wagner
  • (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
    Patent number: 9809559
    Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: November 7, 2017
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Brandon H. Brown, Ernest A. Carra, Jeffrey N. Hemenway, Henry Morrison, Troy Reynolds, Bing Shi, Dimitrios Stefanidis, Fang Wang, Matthew Robert Warr, James Andrew Whitney, Yan Xin
  • (N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOPHENYLAMINO)PYRIMIDIN-4-YL)BENZAMIDE
    Publication number: 20160347719
    Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
    Type: Application
    Filed: August 8, 2016
    Publication date: December 1, 2016
    Inventors: Brandon H. Brown, Ernest A. Carra, Jeffrey N. Hemenway, Henry Morrison, Troy Reynolds, Bing Shi, Dimitrios Stefanidis, Fang Wang, Matthew Robert Warr, James Andrew Whitney, Yan Xin
  • (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
    Patent number: 9469613
    Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: October 18, 2016
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Brandon H. Brown, Ernest A. Carra, Jeffrey N. Hemenway, Henry Morrison, Troy Reynolds, Bing Shi, Dimitrios Stefanidis, Fang Wang, Matthew Robert Warr, James Andrew Whitney, Yan Xin
  • (N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOPHENYLAMINO)PYRIMIDIN-4-YL)BENZAMIDE
    Publication number: 20150361050
    Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
    Type: Application
    Filed: June 11, 2015
    Publication date: December 17, 2015
    Inventors: Brandon H. Brown, Ernest A. Carra, Jeffrey N. Hemenway, Henry Morrison, Troy Reynolds, Bing Shi, Dimitrios Stefanidis, Fang Wang, Matthew Robert Warr, James Andrew Whitney, Yan Xin
  • N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
    Patent number: RE48285
    Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: October 27, 2020
    Assignee: Sierra Oncology, Inc.
    Inventors: Brandon H. Brown, Ernest A. Carra, Jeffrey N. Hemenway, Henry Morrison, Troy Reynolds, Bing Shi, Dimitrios Stefanidis, Fang Wang, Matthew Robert Warr, James Andrew Whitney, Yan Xin
  • N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
    Patent number: RE49445
    Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: March 7, 2023
    Assignee: Sierra Oncology, Inc.
    Inventors: Brandon H. Brown, Ernest A. Carra, Jeffrey N. Hemenway, Henry Morrison, Troy Reynolds, Bing Shi, Dimitrios Stefanidis, Fang Wang, Matthew Robert Warr, James Andrew Whitney, Yan Xin